Alessia Mennitto (A Mennitto)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 7

Top Topics

Renal Cell Carcinoma

Top Venues

International journal of molecular sciences

Expert review of anticancer therapy

Expert review of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Marco Stellato, Sebastiano Buti, Marco Maruzzo, Melissa Bersanelli, Francesco Pierantoni, Ugo De Giorgi, Marilena Di Napoli, Roberto Iacovelli, Maria Giuseppa Vitale, Paola Ermacora, Andrea Malgeri, Brigida Anna Maiorano, Veronica Prati, Alessia Mennitto, Alessia Cavo, Matteo Santoni, Claudia Carella, Lucia Fratino, Giuseppe Procopio, Elena Verzoni, Daniele Santini
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). International journal of molecular sciences 24 (2) (2023)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, Melissa Bersanelli, Francesco Pierantoni, Ugo De Giorgi, Marilena Di Napoli, Roberto Iacovelli, Maria Giuseppa Vitale, Paola Ermacora, Andrea Malgeri, Brigida Anna Maiorano, Veronica Prati, Alessia Mennitto, Alessia Cavo, Matteo Santoni, Claudia Carella, Lucia Fratino, Giuseppe Procopio, Elena Verzoni, Daniele Santini
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). International journal of molecular sciences 24 (2) (2023)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, Melissa Bersanelli, Francesco Pierantoni, Ugo De Giorgi, Marilena Di Napoli, Roberto Iacovelli, Maria Giuseppa Vitale, Paola Ermacora, Andrea Malgeri, Brigida Anna Maiorano, Veronica Prati, Alessia Mennitto, Alessia Cavo, Matteo Santoni, Claudia Carella, Lucia Fratino, Giuseppe Procopio, Elena Verzoni, Daniele Santini
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). International journal of molecular sciences 24 (2) (2023)
Carlo Cattrini, Orazio Caffo, Ugo De Giorgi, Alessia Mennitto, Alessandra Gennari, David Olmos, Elena Castro
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review. Cancers 14 (7) (2022)
Alessia Mennitto, Emma Zattarin, Massimo Di Maio, Davide Bimbatti, Ugo De Giorgi, Sebastiano Buti, Daniele Santini, Chiara Casadei, Mariella Sorarù, Carlo Messina, Claudia Mucciarini, Giuseppe Di Lorenzo, Giandomenico Roviello, Consuelo Buttigliero, Marco Stellato, Pierangela Sepe, Melanie Claps, Valentina Guadalupi, Arianna Ottini, Sandro Pignata, Filippo G De Braud, Elena Verzoni, Giuseppe Procopio
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). Expert review of anticancer therapy (2021)
Alessia Mennitto, Elena Verzoni, F Cognetti, Rosalba Miceli, M Milella, A Mosca, V E Chiuri, A Bearz, Franco Morelli, C Ortega, Francesco Atzori, M Donini, Melanie Claps, Valentina Guadalupi, P Sepe, Vera Cappelletti, Filippo G De Braud, Giuseppe Procopio
Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial. Expert review of clinical pharmacology 14 (2) (2021)
Raffaele Ratta, Elena Verzoni, Alessia Mennitto, Francesco Pantano, Antonia Martinetti, Alessandra Raimondi, Pierangela Sepe, Elisa Sottotetti, Roberta Mennitto, Daniele Morelli, Daniele Santini, Filippo G de Braud, Giuseppe Procopio
Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. Tumori 107 (6) (2020)